MedTrace Logo

First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

NCT07752121 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2026-08-07

No results posted yet for this study

Summary

This study will observe adults with lower-risk myelodysplastic neoplasms (MDS) who have anemia requiring regular red blood cell transfusions and who are prescribed first-line luspatercept as part of routine medical care. The study will follow participants for up to 2 years to understand how often treatment leads to periods without transfusions, changes in hemoglobin levels, health-related quality of life, and safety outcomes. Information on treatment use and outcomes in routine clinical practice in Germany will also be collected.

Conditions

  • Myelodysplastic Neoplasms

Interventions

DRUG

Luspatercept

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-24
Primary Completion
2030-08-31
Completion
2030-08-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07752121 on ClinicalTrials.gov